Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?

Blockhead12-16

The weight-loss drugs space is blazing hot, grabbing and holding Wall Street's attention. Big Pharma leaders Eli Lilly (LLY) and Novo Nordisk (NVO) dominate the market. But other challengers have ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2491994316?lang=en_US&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2024/03/Stock-weightlossdrug-01-shutt-150x150.jpg","is_english":true,"pubTime":"2024-12-16 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2491994316","market":"sg","top_or_hot":-1,"title":"Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?","media":"Blockhead","content":"<div>\n<p>The weight-loss drugs space is blazing hot, grabbing and holding Wall Street's attention.\nBig Pharma leaders Eli Lilly (LLY) and Novo Nordisk (NVO) dominate the market. But other challengers have ...</p>\n\n<a href=\"https://www.investors.com/news/technology/weight-loss-drugs-eli-lilly-novo-nordisk/\">Source Link</a>\n\n</div>\n","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Battle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBattle Over Weight-Loss Drugs: Can Eli Lilly, Novo Nordisk Defend Their Turf?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-16 21:00 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/news/technology/weight-loss-drugs-eli-lilly-novo-nordisk/><strong>Blockhead</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The weight-loss drugs space is blazing hot, grabbing and holding Wall Street's attention.\nBig Pharma leaders Eli Lilly (LLY) and Novo Nordisk (NVO) dominate the market. But other challengers have ...</p>\n\n<a href=\"https://www.investors.com/news/technology/weight-loss-drugs-eli-lilly-novo-nordisk/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2023250504.SGD","symbol_name":"Allianz Thematica Cl AMg DIS H2-SGD","start_time":0,"source_url":"https://www.investors.com/news/technology/weight-loss-drugs-eli-lilly-novo-nordisk/","article_id":"2491994316","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2024/03/Stock-weightlossdrug-01-shutt-150x150.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2491994316","pubTimestamp":1734354059,"columns":[],"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"The weight-loss drugs battle has grabbed Wall Street's attention and stoked shares of Eli Lilly and Novo Nordisk. But others are coming.","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","PFE":"辉瑞","NVO":"诺和诺德","GPCR":"STRUCTURE THERAPEUTICS INC SPON ADS EACH REP 3 ORD","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","BK4550":"红杉资本持仓","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","LU0097036916.USD":"贝莱德美国增长A2 USD","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0882574055.USD":"富达全球健康医疗A ACC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","AMGN":"安进","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","VKTX":"Viking Therapeutics, Inc.","NVO.AU":"NOVO RESOURCES CORP-CDI","03165":"华夏欧优股对冲","LU0354030511.USD":"ALLSPRING  U.S. LARGE CAP GROWTH \"I\" (USD) ACC","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","REGN":"再生元制药公司","LU0882574139.USD":"富达环球消费行业基金A ACC","LLY":"礼来","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","RHHBY":"罗氏控股","BK4532":"文艺复兴科技持仓","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","PFE.AU":"PANTERA MINERALS LTD","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4139":"生物科技","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","LU2211815571.USD":"ALLIANZ POSITIVE CHANGE \"AT\" (USD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC"},"translate_title":"减肥药之争：礼来、诺和诺德能否捍卫自己的地盘？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMGN":1,"VKTX":1,"RHHBY":1,"REGN":1,"PFE.AU":1,"PFE":1,"NVO.AU":1,"NVO":1,"LLY":1,"GPCR":1,"03165":0.6},"content_text":"The weight-loss drugs space is blazing hot, grabbing and holding Wall Street's attention.\nBig Pharma leaders Eli Lilly (LLY) and Novo Nordisk (NVO) dominate the market. But other challengers have joined the fray, from other major companies like Pfizer (PFE), Amgen (AMGN) and Roche (RHHBY) to smaller players like Viking Therapeutics (VKTX).\n\n\n\n↑\nX\n\n\n\n\nThe Weight-Loss Drug Market Is Hot. Which Medical Stock Will Win The Battle For Supremacy?\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nThe Weight-Loss Drug Market Is Hot. Which Medical Stock Will Win The Battle For Supremacy?\n\n\n\n\nThe drugs themselves continue to evolve — and get better. The next-gen obesity treatments could swap needles for pills, require fewer doses and have a better side-effect profile.\nBut this story isn't just about the makers of drugs for shedding pounds. Other storylines and battle lines have emerged.\nCompanies like Regeneron Pharmaceuticals (REGN) stress the importance of drugs that eliminate fat but not muscle. Weight-loss drugs have created a stir among makers of sleep apnea devices and dialysis machines worried that these treatments could lead to a dip in demand. Then, there's the battle between market leaders Eli Lilly and Novo Nordisk and pharmacies licensed to make knockoffs.\nOne thing is clear, an important one for Wall Street: Weight-loss drugs are a fast growing market, projected to be worth $100 billion by 2030, according to some estimates.\nInvestor's Business Daily's Allison Gatlin has been covering what has become an important biopharma story. Bookmark this page to stay on top of the latest obesity and weight-loss drugs news.\n Is Eli Lilly Stock A Buy After Zepbound Bests Wegovy In A Head-To-Head Study?Eli Lilly stock is yo-yoing in December after the company's weight-loss drug, Zepbound, topped Novo Nordisk's rival, Wegovy, in the first-ever head-to-head study. Participants with obesity and one other medical condition —... Read More The Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion MarketAn age-old battle in pharmaceuticals could further rattle Eli Lilly stock and its potential $100 billion market in weight-loss drugs. The showdown centers on compounders, companies allowed to create knockoffs of drugs... Read More Battle Of The Weight-Loss Behemoths: Eli Lilly Whomps Novo NordiskEli Lilly said Wednesday its obesity drug Zepbound spurred more weight loss than Novo Nordisk's Wegovy in the first-ever head-to-head study. The study focused on patients with obesity and one medical problem... Read More Amgen Dives 5% Despite 'Truly Remarkable' Results For Obesity TreatmentAmgen stock tumbled Tuesday after its highly anticipated weight-loss drug met Wall Street's expectations, but didn't beat out Eli Lilly's blockbuster, Zepbound. Over the course of a year, nondiabetic patients who received... Read More Novo Nordisk Slumps On Tightened Outlook As Wegovy Beats, But Ozempic LagsNovo Nordisk stock skidded Wednesday on mixed third-quarter results as sales of weight-loss drug Wegovy beat expectations, but Ozempic came in light. Both drugs use the same active ingredient, semaglutide. Semaglutide mimics... Read More\nSee More News And Analysis On Weight Loss Drugs\n\nWeight-Loss Drugs: New Rivals Arrive\nThe two leading weight-loss drugs today are Wegovy from Novo Nordisk and Zepbound from Eli Lilly. Together, they are expected to generate more than $45 billion in sales in 2029, the latest year for which FactSet has estimates.\nBoth rely on a mechanism long used in diabetes treatment: mimicking the GLP-1 hormone. Doing so improves feelings of satiety and markers of blood sugar. Eli Lilly's Zepbound loops in a second target, the GIP receptor, or GIPR. Lilly's approach has proved to be the stronger one in testing.\nIn a head-to-head study run by Eli Lilly, Zepbound patients lost up to 20.2% of their body weight, or about 50 pounds, over 72 weeks. In comparison, Wegovy patients lost 13.7% of their body weight, which translates to about 33 pounds.\nBut new entrants could loop in additional targets to stoke better weight loss. Companies like Viking and Amgen are also working on weight-loss drugs that might require fewer doses. Amgen's MariTide is being tested \"monthly or less.\" Pfizer, Structure Therapeutics (GPCR), Roche and others are also working on pills as a possible maintenance option for weight loss.\nStill, others hope to improve on the composition of the weight loss — leaning more toward fat than lean muscle mass. So, Eli Lilly and Novo Nordisk have their work cut out to maintain their lead among weight-loss drugs.\nDaniel Chancellor, the vice president of thought leadership at Norstella, says there's room for more players in the massive market. Norstella is an advisory firm for the life sciences industry.\n\"There absolutely is space for other companies to enter obesity,\" he told Investor's Business Daily. \"The larger any market gets, the more fragmentation there will be. I think it's improbable that Lilly and Novo will continue to innovate and continue to dominate (when their) next generation competes against the next generations of other companies.\"\n\nFollow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.\nYOU MAY ALSO LIKE:\nThe Weight-Loss Battle That Could Rattle Eli Lilly's $100 Billion Market\nThe Cream Of The Crop: 5 Biotechs That Outrank Most Stocks\nJoin IBD Live For Stock Ideas Each Morning Before The Open\nGenerate New Stock Ideas With IBD Stock Screener\nIdentify Bases And Buy Points With This Pattern Recognition Tool","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2491994316"}